Evidence map›Paper›PMID 30700598›Full record

Trial reportJournal of virology2019

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.

Line K Vibholm, Julio C C Lorenzi, Joy A Pai, Yehuda Z Cohen, Thiago Y Oliveira, John P Barton, Marco Garcia Noceda, Ching-Lan Lu, Yuria Ablanedo-Terrazas, Perla M Del Rio Estrada and 6 more

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Line K VibholmDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-8945-1905
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Joy A PaiLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Yehuda Z CohenLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.ORCID 0000-0001-6987-1478
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
John P BartonDepartment of Physics and Astronomy, University of California, Riverside, California, USA.
Marco Garcia NocedaDepartment of Physics and Astronomy, University of California, Riverside, California, USA.
Ching-Lan LuLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Yuria Ablanedo-TerrazasCenter for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Perla M Del Rio EstradaCenter for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Gustavo Reyes-TeranCenter for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Martin TolstrupDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Paul W DentonDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Tine DamsgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Ole S SøgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA nussen@rockefeller.edu.
Aarhus University · DKRockefeller University · USUniversity of California, Riverside · USHoward Hughes Medical Institute · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Laurie J Bauman · 2017 to 2026
$28.3M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M
Exploring the dynamics and composition of the latent HIV reservoir by analyzing the diversity of the replication-competent reservoirK23AI136578 · NIAID · ROCKEFELLER UNIVERSITY · PI COHEN, YEHUDA Z · 2018 to 2018
$122k
NIAID NIH HHS K23 AI136578NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

The role of lymphoid tissue as a potential source of HIV-1 rebound following interruption of antiretroviral therapy (ART) is uncertain. To address this issue, we compared the latent viruses obtained from CD4

Indexed as

CD4-Positive T-LymphocytesHIV InfectionsLymph NodesAdultAnti-Retroviral AgentsDNA, ViralFemaleHIV-1HumansMaleMiddle AgedProvirusesToll-Like Receptor 9Anti-Retroviral AgentsDNA, ViralTLR9 protein, humanToll-Like Receptor 9ATIHIV-1infectious diseaseslymph noderecombination

Identifiers

PMID30700598
PMCPMC6450127
OpenAlexW2949650899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.